Global Community Acquired Pneumonia Drugs Market, By Type (Bacterial, Virus, Fungi), Drug Class (Pleuromutilin Antibiotic, Cephalosporin, Glycylcycline, Oxazolidinone, Ketolide, Others), Dosage Form (Solution, Tablet), Route of Administration (Oral, Intravenous), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2029
Market Analysis and Size
In recent years, the community acquired pneumonia drugs market is anticipated to grow rapidly during the forecast period. Cough, fever, chills, lethargy, dyspnea, rigors, and pleuritic chest discomfort are common symptoms of community-acquired pneumonia. When a patient appears with probable community-acquired pneumonia, the physician should use a mortality prediction tool, such as the Pneumonia Severity Index, in conjunction with clinical judgement to determine whether the patient requires hospitalization. Several organizations' consensus guidelines support empiric treatment with macrolides, fluoroquinolones, or doxycycline. After their symptoms improve, they are afebrile, and they can handle oral drugs; hospitalized patients should be transitioned from parenteral antibiotics to oral antibiotics.
Data Bridge Market Research analyses that the community acquired pneumonia drugs market was valued at USD 1,367.50 million in 2021 and is expected to reach USD 2,475.44 million by 2029, registering a CAGR of 7.70% during the forecast period of 2022 to 2029. The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Market Definition
Community-acquired pneumonia (CAP) is a bacterial or viral infection that damages the lungs. It is prevalent in people who haven't had much involvement with healthcare or medical institutions or organizations. CAP is one of the leading causes of death. The most common bacterial infections that cause CAP are Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. This disease is characterized by the accumulation of fluids in the alveoli of the lungs, which impairs lung function and fever, chest discomfort, and cough. Mental confusion, significant headaches, myalgias, ear pain, abdominal pain, diarrhoea, rashes, nonexudative pharyngitis, hemoptysis, splenomegaly, and relative bradycardia are among the most common symptoms. CAP affects people at all ages, from infants to the elderly.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2019 - 2014)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Bacterial, Virus, Fungi), Drug Class (Pleuromutilin Antibiotic, Cephalosporin, Glycylcycline, Oxazolidinone, Ketolide, Others), Dosage Form (Solution, Tablet), Route of Administration (Oral, Intravenous), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (US), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), Pfizer Inc. (US), GlaxoSmithKline plc (UK), Novartis AG (Switzerland), AstraZeneca (UK), Johnson & Johnson Private Limited (US), Sun Pharmaceutical Industries Ltd. (India), Merck & Co., Inc. (US), Abbott (US), Allergan (Ireland), Takeda Pharmaceutical Company Limited (Japan), Sumitomo Pharma Co., Ltd. (Japan), Melinta Therapeutics LLC (US), Basilea Pharmaceutica Ltd. (Switzerland), Nabriva Therapeutics plc (Ireland)
|
|
Market Opportunities
|
|
Community Acquired Pneumonia Drugs Market Dynamics
Drivers
- Increasing prevalence of community-acquired pneumonia
The rising prevalence of community-acquired pneumonia is estimated to enhance the market's growth. The high frequency of community-acquired pneumonia is likely to fuel demand for CABP treatment medications, which will drive market expansion over the forecast period. According to an article published in 2017, by the Asian Pacific Society of Respirology, the annual incidence of all-cause CAP in Central Vietnam was estimated to be 0.81 per 1,000 people, rising to 6.95 per 1,000 people among those aged 75 and beyond.
- Increasing investment for healthcare infrastructure
Another significant factor influencing the growth rate of community acquired pneumonia drugs market is the rising healthcare expenditure which helps in improving its infrastructure. Also, various government organizations aims to improve the healthcare infrastructure by increasing funding and this will further influence the market dynamics.
- Growing number of geriatric population
The surging geriatric population is estimated to enhance the market's expansion during the forecast period of 2022-2029. According to the World Health Organization (WHO), the worldwide geriatric population, which was estimated to be over 524 million in 2010, is expected to increase to nearly 2 billion by 2050. Due to their compromised immune systems, geriatrics are more susceptible to get'ting community-acquired pneumonia, further estimated to enhance themarket's growth rate.
Furthermore, rising initiatives by public and private organizations to spread awareness will expand the community acquired pneumonia drugs market. Additionally, people's sedentary lifestyle, such as growing addiction to smoking and high consumption of alcohol, will result in the expansion of community acquired pneumonia drugs market.
Opportunities
- Increase in the number of research and development activities
Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the community acquired pneumonia drugs market growth. Along with this, rising drug approvals and launches will further propel the ' 'market's growth rate.
Moreover, rising investment for the development of advanced technologies and increase in the number of emerging markets will further provide beneficial opportunities for the community acquired pneumonia drugs market growth during the forecast period.
Restraints/Challenges
On the other hand, the high cost associated with drug distribution and development will obstruct the market's growth rate. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the community acquired pneumonia drugs market. Additionally, strict regulatory policies and side effects of drugs will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.
This community acquired pneumonia drugs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the community acquired pneumonia drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Patient Epidemiology Analysis
Community acquired pneumonia drugs market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
COVID-19 Impact on Community Acquired Pneumonia Drugs Market
Since its emergence in December 2019, the COVID-19 virus has spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency. COVID-19, a new coronavirus, was identified as the causal agent in the pneumonia cases. This virus spread quickly over the world, killing a large number of people. COVID-19 was labelled a global pandemic by the World Health Organization (WHO) in March 2020, and rigorous measures to prevent the disease's spread were recommended. Since then, the pandemic has delayed the expansion of the healthcare sector and disrupted the supply chain. Furthermore, governments in many nations had imposed nationwide lockdowns to halt the spread of COVID-19. Similarly, healthcare organizations in numerous nations throughout the world were having difficulty continuing their supply chain activities. The community acquired pneumonia drugs market was hampered by the supply chain slowness. However, now that COVID-19 vaccines are readily available, numerous authorities are trying to assure that life-saving medications and vaccines are supplied without interruption. As a result, the market is projected to stabilize in the future.
Global Community Acquired Pneumonia Drugs Market Scope
The community acquired pneumonia drugs market is segmented on the basis of type, drug class, dosage form, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Bacterial
- Virus
- Fungi
Drug Class
- Pleuromutilin Antibiotic
- Cephalosporin
- Glycylcycline
- Oxazolidinone
- Ketolide
- Others
Dosage Form
- Solution
- Tablet
Route of Administration
- Oral
- Intravenous
End-Users
- Hospitals
- Specialty Clinics
- Homecare
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Community Acquired Pneumonia Drugs Market Regional Analysis/Insights
The community acquired pneumonia drugs market is analysed and market size insights and trends are provided by country, type, drug class, dosage form, route of administration, end-users and distribution channel as referenced above.
The countries covered in the community acquired pneumonia drugs market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
North America dominates the community acquired pneumonia drugs market because of this region's increasing research and development activities. Additionally, rising healthcare expenditure and presence of major key players will further propel the ' 'market's growth rate in this region.
Asia-Pacific is expected to grow during the forecast period of 2022 to 2029 due to increased research and developments on pneumonia drugs in this region. Also, development of healthcare infrastructure and rising government initiatives will further propel the ' 'market's growth rate in this region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Community Acquired Pneumonia Drugs Market Share Analysis
The community acquired pneumonia drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to community acquired pneumonia drugs market.
Some of the major players operating in the community acquired pneumonia drugs market are:
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Mylan N.V. (US)
- Teva Pharmaceutical Industries Ltd.(Israel)
- Sanofi (France)
- Pfizer Inc. (US)
- GlaxoSmithKline plc (UK)
- Novartis AG (Switzerland)
- AstraZeneca (UK)
- Johnson & Johnson Private Limited (US)
- Sun Pharmaceutical Industries Ltd. (India)
- Merck & Co., Inc. (US)
- Abbott (US)
- Allergan (Ireland)
- Takeda Pharmaceutical Company Limited (Japan)
- Sumitomo Pharma Co., Ltd. (Japan)
- Melinta Therapeutics LLC (US)
- Basilea Pharmaceutica Ltd. (Switzerland)
- Nabriva Therapeutics plc (Ireland)
SKU-